Filings & corporate actions
- 13 NovresultsResults · Q2 FY27 · consolidated and standalone+4.1%NSE
- 27 OctshareholdingShareholding · 23 Oct 2026+0.3%NSE
- 22 OctshareholdingShareholding · 30 Sept 2026+0.2%NSE
- 18 SeptdividendDividend · ₹1.00 per share · record 19 Sept 2026-5.3%
- 14 AugresultsResults · Q1 FY27 · consolidated and standalone-8.6%NSE
- 16 JulshareholdingShareholding · 30 Jun 2026+0.7%NSE
- 27 MayresultsResults · Q4 FY26 · consolidated and standalone-4.6%NSE
- 16 AprshareholdingShareholding · 31 Mar 2026+0.4%NSE
- 13 FebresultsResults · Q3 FY26 · consolidated and standalone-4.0%NSE
- 16 JanshareholdingShareholding · 31 Dec 2025-3.1%NSE
Reaction to results · all yearsrose on day 0 in 6 of 21 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 13 Nov 2026 | +4.1% | — | — | 1.7× |
| Q1 FY27 | 14 Aug 2026 | -8.6% | -2.9% | +32.3% | 4.3× |
| Q4 FY26 | 27 May 2026 | -4.6% | -13.7% | -15.2% | 3.7× |
| Q3 FY26 | 13 Feb 2026 | -4.0% | -14.4% | -23.5% | 1.2× |
| Q2 FY26 | 14 Nov 2025 | -3.5% | -2.3% | -3.9% | 1.8× |
| Q1 FY26 | 12 Aug 2025 | -3.7% | +1.1% | -4.1% | 1.3× |
| Q4 FY25 | 30 May 2025 | -2.3% | -1.5% | -2.8% | 2.2× |
| Q3 FY25 | 11 Feb 2025 | -2.0% | +4.8% | -8.9% | 2.2× |
| Q2 FY25 | 15 Nov 2024 | +0.3% | -2.0% | +22.8% | 0.3× |
| Q1 FY25 | 13 Aug 2024 | -4.3% | +2.2% | +9.2% | 1.7× |
| Q4 FY24 | 29 May 2024 | -4.8% | -4.6% | -10.3% | 1.1× |
| Q3 FY24 | 12 Feb 2024 | +8.3% | +15.0% | -16.7% | 13.7× |
| Q2 FY24 | 10 Nov 2023 | 0.0% | -1.2% | -10.1% | 0.2× |
| Q1 FY24 | 8 Aug 2023 | +0.9% | -6.1% | -14.5% | 1.3× |
| Q4 FY23 | 31 May 2023 | -3.3% | -2.5% | +3.2% | 1.5× |
| Q3 FY23 | 10 Feb 2023 | -2.7% | -7.3% | -16.0% | 0.5× |
| Q2 FY23 | 11 Nov 2022 | -4.8% | -6.7% | -8.2% | 0.9× |
| Q1 FY23 | 10 Aug 2022 | -0.8% | +13.2% | +43.6% | 0.9× |
| Q4 FY22 | 25 May 2022 | +2.2% | +16.6% | -3.6% | 1.3× |
| Q3 FY22 | 8 Feb 2022 | -7.2% | -16.8% | -21.7% | 3.0× |
| Q2 FY22 | 3 Nov 2021 | +16.0% | +6.3% | +16.4% | — |
| Average | -1.2% | -1.1% | -1.6% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +7.6% | +9.6% | +14.6% | — | — | — |
| Profit | +28.9% | -4.0% | -4.2% | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions MEDICAMEQ settled 100.0% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 66.4%, so recent sessions are running 33.6 points higher than usual. That is the highest reading in the 1,253 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.52% | +1.51% | +7.83% | +17.29% | +7.14% | -30.38% |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 46.9 | 60.6 | 47.9 | 54.8 |
| YoY chg | +3.9% | +104.8% | +11.3% | +16.2% |
| Net profit (₹ Cr) | 1.6 | 4.4 | 1.8 | 4.1 |
| YoY chg | -44.1% | +138.6% | +15.3% | +94.8% |
| Net margin | 3.5% | 7.3% | 3.9% | 7.5% |
| EPS | 1.21 | 3.28 | 1.36 | 3.04 |
Shareholding over time
By quarter
23 Oct 2026 · promoter 42.57% · public 57.43%- Promoter
- Public and others
- Promoter
- 42.57%
- Public
- 57.43%
- Promoter change
- +2.11 pp
- Filed
- 27 Oct 2026
- FII
- 4.35%
- DII
- 0.00%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 0.00%
- Insurance
- 0.00%
- FPI
- 0.02%
- Retail ≤ ₹2L
- 26.00%
- HNI > ₹2L
- 6.02%
- NRI
- 1.00%
- Bodies corporate
- 2.00%
- Shareholders
- 11,662
0.00 pp QoQ
0.00 pp QoQ
+0.02 pp QoQ
-0.54 pp QoQ
-0.59 pp QoQ
-0.03 pp QoQ
-0.07 pp QoQ
-0.2% QoQ
Major holders
As of 23 Oct 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| SHIVALIK RASAYAN LIMITED | Promoter · Corporate | 42.57% | 59.87L |
| PHARMADANICA A/S | Corporate | 9.53% | 13.40L |
| GINNERUP CAPITAL APS | Corporate | 2.52% | 3.55L |
| INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS | Other | 1.21% | 1.71L |
| RAJESH MADAN | Individual | 1.10% | 1.54L |
| VIJAY AMICHAND SANGHVI | Individual | 1.08% | 1.52L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2026-27 | 1 | ₹1.00 | ₹1.00 |
| FY2025-26 | 1 | ₹1.00 | ₹1.00 |
| FY2024-25 | 1 | ₹1.00 | ₹1.00 |
| FY2023-24 | 1 | ₹1.00 | ₹1.00 |
| FY2022-23 | 1 | ₹1.00 | ₹1.00 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 18 Sept 2026 | 19 Sept 2026 | ₹1.00 | ₹1.00 |
| 19 Sept 2025 | — | ₹1.00 | ₹1.00 |
| 19 Sept 2024 | — | ₹1.00 | ₹1.00 |
| 20 Sept 2023 | — | ₹1.00 | ₹1.00 |
| 19 Sept 2022 | — | ₹1.00 | ₹1.00 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
Price-band hits
Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.
Book closures & record dates
NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- −₹1.1Cr
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- 2.7 years ago
- Disclosures on record
- 28
| Broadcast | Person | Side | Shares | Value | Price | Holding before → after | Stake | Regulation |
|---|---|---|---|---|---|---|---|---|
| 30 Sept 2026 | Sanjay BansalDirector | Sell | 32.8K | ₹1.1Cr | 321.29 | 1.03L → 70.0K | 0.51%-0.24 pp | 7(2)told 30 Sept 2026 |
| 18 Sept 2024 | Geetika MadanOther | Sell | 1.5K | ₹7.1L | 475.86 | 31.5K → 30.0K | 0.23%-0.01 pp | 7(3)told 17 Sept 2024 |
| 18 Sept 2024 | Geetika MadanOther | Sell | 1.0K | ₹4.0L | 398.20 | 32.5K → 31.5K | 0.24%-0.01 pp | 7(3)told 17 Sept 2024 |
| 26 Mar 2024 | Geetika MadanOther | Sell | 2.4K | ₹10.5L | 428.07 | 36.9K → 34.5K | 0.27%-0.02 pp | 7(3)told 26 Mar 2024 |
| 23 Mar 2024 | Growel Remedies LimitedPromoter | Sell | 2.00L | ₹8.4Cr | 419.43 | 2.00L → — | 0.00% | 7(2)told 23 Mar 2024 |
| 23 Mar 2024 | Shivalik Rasayan limitedPromoter | Buy | 2.00L | ₹8.5Cr | 424.36 | 52.66L → 54.66L | 42.99%+1.57 pp | 7(2)told 23 Mar 2024 |
| 18 Mar 2024 | Geetika MadanOther | Sell | 28.1K | ₹1.1Cr | 383.97 | 65.0K → 36.9K | 0.29%-0.22 pp | 7(3)told 16 Mar 2024 |
| 8 Mar 2024 | Geetika MadanOther | Sell | 5.5K | ₹25.6L | 462.59 | 70.6K → 65.0K | 0.51%-0.04 pp | 7(3)told 8 Mar 2024 |
| 6 Mar 2024 | Geetika MadanOther | Sell | 2.8K | ₹13.6L | 486.01 | 73.4K → 70.6K | 0.56%-0.02 pp | 7(3)told 5 Mar 2024 |
| 2 Mar 2024 | Geetika MadanRelative | Sell | 73.4K | ~₹3.6Cr | 486.70 | 77.5K → 4.1K | 0.58%-10.33 pp | 7(2)told 1 Mar 2024 |
| 3 Jan 2022 | Growel Remedies LimitedPromoter | Sell | 25.0K | ₹2.3Cr | 904.95 | 2.25L → 2.00L | 1.64%-0.20 pp | 7(2)told 3 Feb 2022 |
| 31 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 29.0K | ₹2.7Cr | 940.06 | 2.54L → 2.25L | 1.84%-0.24 pp | 7(2)told 31 Dec 2021 |
| 29 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 46.0K | ₹4.5Cr | 987.71 | 3.00L → 2.54L | 2.08%-0.38 pp | 7(2)told 29 Dec 2021 |
| 21 Dec 2021 | Shivalik Rasayan LimitedPromoter | Buy | 200 | ₹1.5L | 758.30 | 51.26L → 51.26L | 41.96%+0.00 pp | 7(2)told 21 Dec 2021 |
| 21 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 1.6K | ₹12.9L | 815.37 | 3.02L → 3.00L | 2.46%-0.01 pp | 7(2)told 21 Dec 2021 |
| 18 Dec 2021 | Shivalik Rasayan LimitedPromoter | Buy | 100 | ₹77,690 | 776.90 | 51.26L → 51.26L | 41.96%+0.00 pp | 7(2)told 18 Dec 2021 |
| 18 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 7.5K | ₹62.2L | 832.42 | 3.09L → 3.02L | 2.47%-0.06 pp | 7(2)told 18 Dec 2021 |
| 16 Dec 2021 | Shivalik Rasayan LimitedPromoter | Buy | 7.1K | ₹51.3L | 723.57 | 51.19L → 51.26L | 41.96%+0.06 pp | 7(2)told 16 Dec 2021 |
| 16 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 23.5K | ₹1.9Cr | 793.23 | 3.33L → 3.09L | 2.53%-0.19 pp | 7(2)told 16 Dec 2021 |
| 15 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 25.5K | ₹2.0Cr | 766.51 | 3.58L → 3.33L | 2.72%-0.21 pp | 7(2)told 13 Dec 2021 |
| 15 Dec 2021 | Shivalik Rasayan LimitedPromoter | Buy | 10.2K | ₹77.4L | 757.17 | 51.08L → 51.19L | 41.90%+0.08 pp | 7(2)told 13 Dec 2021 |
| 14 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 20.5K | ₹2.0Cr | 953.47 | 3.58L → 3.38L | 2.76%-0.17 pp | 7(2)told 13 Dec 2021 |
| 10 Dec 2021 | Shivalik Rasayan LimitedPromoter | Buy | 3.4K | ₹24.6L | 725.41 | 51.05L → 51.08L | 41.82%+0.03 pp | 7(2)told 10 Dec 2021 |
| 10 Dec 2021 | Growel Remedies LimitedPromoter | Sell | 14.0K | ₹1.0Cr | 741.17 | 3.72L → 3.58L | 2.93%-0.11 pp | 7(2)told 9 Dec 2021 |
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Filings
CSVBulk & block deals · 22 Mar 2024
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 22 Mar 2024 | Sell · bulk | GROWEL REMEDIES LIMITED | 2.00L | 421.86 | ₹8.4Cr |
| 22 Mar 2024 | Buy · bulk | SHIVALIK RASAYAN LIMITED | 2.00L | 421.86 | ₹8.4Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.
Exchange surveillance
- ESM · stage 1 · since 17 Sept 2026 — Enhanced Surveillance Measure, for companies under ₹500 crore: a 5% or 2% price band and trade-for-trade settlement.
Price band: 5% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.
Every stock on this session →Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 46.5 | 47.3 | 43.0 | 44.7 | 45.1 | 29.6 | 43.0 | 47.2 | 46.9 | 60.6 | 47.9 | 54.8 | |
| Other income | 0.8 | 0.6 | 0.6 | 0.3 | 0.1 | 5.2 | 0.5 | 0.4 | 0.5 | 1.7 | 0.9 | (0.0) | |
| Total income | 47.3 | 47.9 | 43.6 | 45.0 | 45.3 | 34.8 | 43.5 | 47.5 | 47.4 | 62.4 | 48.8 | 54.8 | |
| Total expenses | 44.1 | 45.2 | 42.1 | 43.1 | 41.4 | 32.4 | 41.4 | 44.9 | 45.3 | 57.3 | 46.2 | 49.7 | |
| └ Finance costs | 0.6 | 1.9 | 0.7 | 1.0 | 0.8 | 0.6 | 1.2 | 1.0 | 1.0 | 0.4 | 0.8 | 1.7 | |
| └ Depreciation | 1.8 | 1.8 | 1.8 | 2.6 | 2.2 | 0.5 | 1.8 | 1.9 | 1.8 | 1.7 | 1.8 | 1.9 | |
| Profit before tax | 3.3 | 2.7 | 1.6 | 2.0 | 3.9 | 2.5 | 2.1 | 2.7 | 2.1 | 5.1 | 2.6 | 5.1 | |
| Tax expense | 1.2 | 0.6 | 0.8 | 1.1 | 1.0 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.7 | 1.0 | |
| Net profit | 2.0 | 2.0 | 0.8 | 0.9 | 2.9 | 1.9 | 1.6 | 2.1 | 1.6 | 4.4 | 1.8 | 4.1 | |
| EPS | 1.60 | 1.61 | 0.63 | 0.71 | 2.30 | 1.47 | 1.18 | 1.56 | 1.21 | 3.28 | 1.36 | 3.04 | |
| Net margin | 4.37% | 4.31% | 1.86% | 2.02% | 6.47% | 6.29% | 3.72% | 4.48% | 3.48% | 7.33% | 3.85% | 7.51% | |
| PBT margin | 7.04% | 5.61% | 3.62% | 4.37% | 8.59% | 8.41% | 4.95% | 5.69% | 4.50% | 8.34% | 5.37% | 9.34% | |
| Tax rate | 37.97% | 23.17% | 48.68% | 53.80% | 24.63% | 25.16% | 24.89% | 21.19% | 22.56% | 12.11% | 28.22% | 19.56% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 13 Nov 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 278.5 | 297.4 | 294.5 | 288.5 | 296.9 | 367.1 | 372.0 | 359.6 | |
| Current assets | 163.4 | 175.5 | 159.6 | 156.8 | 164.5 | 223.4 | 223.7 | 206.3 | |
| └ Cash & equivalents | 20.8 | 13.4 | 14.8 | 6.4 | 3.8 | 43.7 | 31.3 | 34.8 | |
| └ Other bank balances | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.7 | 0.0 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Trade receivables | 65.3 | 74.8 | 55.3 | 56.6 | 68.9 | 77.6 | 81.8 | 68.8 | |
| └ Inventories | 45.1 | 56.3 | 59.4 | 60.0 | 62.1 | 68.8 | 70.1 | 63.4 | |
| Total equity | 193.4 | 199.9 | 200.5 | 215.9 | 212.8 | 275.4 | 275.6 | 281.5 | |
| └ Attributable to owners | 193.4 | 199.9 | 200.5 | 215.9 | 212.8 | 275.4 | 275.6 | 281.5 | |
| └ Share capital | 12.7 | 12.7 | 12.7 | 12.7 | 12.7 | 13.6 | 13.6 | 13.6 | |
| Borrowings | 24.2 | 29.0 | 30.8 | 20.2 | 33.3 | 38.6 | 47.8 | 40.7 | |
| └ Current | 23.3 | 27.1 | 29.6 | 18.8 | 29.5 | 35.0 | 41.6 | 33.1 | |
| └ Non-current | 0.9 | 1.9 | 1.3 | 1.4 | 3.7 | 3.6 | 6.2 | 7.6 | |
| Trade payables | 47.6 | 55.9 | 45.4 | 44.9 | 42.6 | 43.2 | 40.0 | 27.1 | |
| Current liabilities | 82.6 | 94.1 | 91.0 | 68.8 | 78.2 | 85.6 | 87.9 | 67.9 | |
| Total liabilities | 85.1 | 97.5 | 94.0 | 72.6 | 84.1 | 91.7 | 96.4 | 78.1 | |
| Net debt | 3.4 | 15.6 | 16.0 | 13.8 | 29.5 | (5.0) | 13.9 | 5.9 | |
| Debt / equity | 0.13 | 0.15 | 0.15 | 0.09 | 0.16 | 0.14 | 0.17 | 0.14 | |
| Current ratio | 1.98 | 1.87 | 1.75 | 2.28 | 2.11 | 2.61 | 2.54 | 3.04 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (6.3) | (7.6) | (0.4) | (8.5) | (7.2) | (12.4) | (33.2) | 13.6 | |
| └ Capex | (6.6) | (3.9) | (6.3) | (1.2) | (2.1) | (2.2) | (4.8) | 0.0 | |
| Free cash flow | (12.9) | (11.5) | (6.7) | (9.7) | (9.3) | (14.6) | (38.0) | 13.6 | |
| Investing cash flow | (5.9) | (3.8) | (5.6) | (1.1) | (1.9) | (1.5) | (3.0) | (0.4) | |
| Financing cash flow | 29.1 | 4.0 | (0.1) | 1.3 | (1.9) | 53.8 | 63.7 | (9.6) | |
| └ Dividends paid | (1.3) | 0.0 | (1.3) | 0.0 | (1.3) | 0.0 | (1.4) | 0.0 | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | 17.0 | (7.4) | (6.0) | (8.4) | (11.0) | 39.9 | 27.5 | 3.5 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →MEDICAMEQ at a glance
- MEDICAMEQ closed at ₹285.9 on 20 Nov 2026, -0.52% on the day, -30.4% over one year, 36.1% below its 52-week high of ₹447.65.
- Delivery was 100.0% of traded quantity on 20 Nov 2026, the 100th percentile of its own 1,253 sessions with a reading (20-session average 100.0%, 1-year average 66.4%).
- Market capitalisation is ₹402 crore at a trailing P/E of 34.7 (trailing EPS ₹8.23).
- Q2 FY27 results (consolidated, filed 13 Nov 2026): revenue ₹55 crore (+16.2% year on year), net profit ₹4 crore (+94.8%); the price moved +4.1% on the first session after.
- Promoters held 42.57% at 23 Oct 2026, up 2.11 percentage points on the previous filing.
- Q3 FY27 results are expected between 8 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
Other NSE stocks by turnover
- ININNOVANAInnovana Thinklabs Limited286.60+1.02%
- AIAIROLAMAiro Lam limited93.00-2.15%
- ESESSARSHPNGEssar Shipping Limited16.17-0.74%
- ISISFTIntrasoft Technologies Limited117.18+4.75%
- SGSGILSynergy Green Industries Limited551.30+2.02%
- IEIELIEL18.99-5.71%
- BUBUTTERFLYButterfly Gandhimathi Appliances Limited576.20-1.23%
- IRIRISIRIS RegTech Solutions Limited201.83-3.73%
- IFIFGLEXPORIFGL Refractories Limited178.02-1.60%
- SHSHAHShah Metacorp Limited2.59-0.38%
- SASAKHTISUGSakthi Sugars Limited18.52-2.01%
- WIWIMPLASTWIMPLAST335.300.00%